{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-010371","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.036626+00:00","generated_at":"2026-06-04T23:04:32.954360+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bioventus Q4 revenue up 7.6% to $135.4M; guides FY2024 sales $520-535M","bullets":["Q4 revenue $135.4M (+7.6% reported; +14.3% organic); Pain Treatments grew >20%.","Net loss from continuing ops $7.7M vs $35.4M prior year; adjusted EBITDA $22.0M (+28.1%).","Full year 2023 revenue $512.3M (flat YoY); net loss $121.2M vs $144.7M; adj. EBITDA $88.9M (+29.5%).","Appointed Rob Claypoole as President and CEO, effective prior to Q4 close.","FY2024 guidance: net sales $520-535M, adjusted EBITDA $89-94M, non-GAAP EPS $0.12-$0.20."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-010371","json":"https://secwatch.observer/filing/0001628280-24-010371.json","markdown":"https://secwatch.observer/filing/0001628280-24-010371.md","text":"https://secwatch.observer/filing/0001628280-24-010371.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/0001628280-24-010371-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/bvs-20240312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:04:32.954360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"163746068f3421f6002cc77a823d349c57618c94","claim":"Bioventus Inc. reported Fourth Quarter 2023 results: revenue $135.4 million, net income net loss of $7.7 million, EPS ($0.10) loss per share.","evidence_excerpt":"For the fourth quarter, worldwide revenue totaled $135.4 million, an increase of 7.6% compared to the prior year. On an organic* basis, revenue increased 14.3%, driven by more than 20% growth in Pain Treatments and Surgical Solutions. The Company also reported a fourth quarter net loss from continuing operations of $7.7 million, compared to net loss from continuing operations of $35.4 million in the prior-year period. Adjusted EBITDA* from continuing operations of $22.0 million advanced 28.1% from $17.2 million last year due to strong revenue growth and disciplined cost management. Loss per share of Class A common stock from continuing operations was $0.10 per share, compared to a loss of $0.40 per share last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/0001628280-24-010371-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter 2023"},{"label":"Revenue","value":"$135.4 million"},{"label":"Net income","value":"net loss of $7.7 million"},{"label":"EPS","value":"($0.10) loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4297151886f8eb5a728621001cf2c2c86dddf2dd","claim":"Bioventus Inc. reported Full Year 2024 results: revenue $520 million to $535 million, EPS $0.12 to $0.20. Guidance initiated.","evidence_excerpt":"Bioventus introduced its financial guidance for full-year 2024. The Company expects: • Net sales of $520 million to $535 million • Adjusted EBITDA* of $89 million to $94 million • Non-GAAP EPS* of $0.12 to $0.20","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/0001628280-24-010371-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2024"},{"label":"Revenue","value":"$520 million to $535 million"},{"label":"EPS","value":"$0.12 to $0.20"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"b1296d3a70e99170ef630fcfc57faf13eab9225b","claim":"Bioventus Inc. reported Full Year 2023 results: revenue $512.3 million, net income net loss of $121.2 million, EPS ($1.54) loss per share.","evidence_excerpt":"Bioventus’ full-year 2023 worldwide revenue totaled $512.3 million, which was even compared to the prior year. On an organic* basis, revenue increased 3.6%, driven by 9.4% growth in Surgical Solutions. The Company also reported a full-year 2023 net loss from continuing operations of $121.2 million, compared to net loss from continuing operations of $144.7 million in the prior year. Adjusted EBITDA from continuing operations* of $88.9 million advanced 29.5% from $68.6 million last year due to disciplined cost management and savings from a corporate restructuring implemented at the beginning of the year. Loss per share of Class A common stock from continuing operations was $1.54 per share, compared to a loss of $1.70 per share last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/0001628280-24-010371-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2023"},{"label":"Revenue","value":"$512.3 million"},{"label":"Net income","value":"net loss of $121.2 million"},{"label":"EPS","value":"($1.54) loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}